Presalvage International Staging System Stage and Other Important Outcome Associations in CD34⁺-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

ABSTRACT: Despite ongoing therapeutic advances, multiple myeloma (MM) remains largely incurable, and outcomes in patients who develop resistance to immunomodulatory drugs or proteasome inhibitors remain grim. Allogeneic hematopoietic cell transplantation (alloHCT) is an alternative option that may offer potential for cure. Although rates of transplantation-related morbidity and mortality have decreased in recent years, weighing this approach's potential benefits against nontransplantation therapies demands a thoroughly informed pre-alloHCT assessment. Here we assess the impact of pre-alloHCT variables on important clinical outcomes in a large cohort of relapsed refractory MM (RRMM) CD34⁺-selected alloHCT recipients. We included all patients with MM who underwent CD34⁺-selected

SUBMITTER: Bryant AR 

PROVIDER: S-EPMC7470026 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature